tofacitinib

P3, N=118, Recruiting, Pfizer | Active, not recruiting --> Recruiting

The review was enriched by the inclusion of a new case: a 60-year-old woman who developed anti-MDA5-positive dermatomyositis two weeks after receiving her fourth dose of the BNT162b2 (Pfizer/BioNTech) vaccine. Treatment with oral prednisone, intravenous alprostadil, and the Janus kinase inhibitor tofacitinib resulted in marked clinical improvement. This case, together with the literature review, illustrates both typical and atypical presentations of vaccine-associated anti-MDA5 DM, highlights diagnostic challenges without lung involvement, and suggests JAK inhibition as a potential therapeutic option, contributing to a more comprehensive understanding of post-vaccination dermatomyositis.

P=N/A, N=186, Recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting --> Recruiting

P=N/A, N=80, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Increased use of JAKi in the management of IMIDs is ongoing and will accelerate if the positive results noted in trials for lupus, inflammatory myopathies, and psoriatic arthritis result in regulatory approval. The article highlighted in this review provide an update on the progress being made in newer rheumatic disease indications as well as efforts to better understand the adverse event profile for patients on treatment.

P4, N=34, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Several studies have confirmed that chlorogenic acid (CGA) has beneficial effects on intestinal health. This effect was comparable to that of Tofacitinib, a known JAK/STAT pathway inhibitor. Collectively, these findings suggest that CGA protects intestinal epithelial integrity and alleviates intestinal injury by suppressing inflammatory responses and preserving ISC activity via inhibition of the JAK/STAT signaling pathway.

Agreed positions included caution with JAK inhibitors (JAKi) in older patients and in those with CV/VTE risk; preference for IL-6 receptor inhibitors or JAKi for monotherapy or prominent systemic inflammation; in RA-ILD, use a b/tsDMARD with a non-TNFi mechanism; rituximab as first choice in rheumatoid vasculitis; abatacept in infection-prone patients; discouraging JAKi in prior malignancy; and TNFi as acceptable during pregnancy. Two statements did not reach consensus: preferential use of non-TNFi in obesity and heightened caution with tofacitinib in osteoporosis or fracture risk. This Delphi-validated, profile-based framework provides a practical tool to support evidence-informed clinical decision-making.

P4, N=60, Completed, Universita' Degli Studi Di Roma Tor Vergata | Recruiting --> Completed

P2, N=66, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting

P3, N=118, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

P3, N=400, Recruiting, Duke University | Not yet recruiting --> Recruiting